Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Global Alliance for TB Drug Development

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 2000-01-01

Employees: 51

Market Cap: -

Website: http://www.tballiance.org

Clinical Trials

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

Phase 2

Active, not recruiting

Conditions: Pulmonary TB
Pulmonary Tuberculosis
Drug Sensitive Tuberculosis

Interventions: Drug: TBAJ-876
Drug: HRZE
Drug: Pretomanid
Drug: Linezolid
Drug: Bedaquiline
Drug: HR

First Posted Date: 2023-09-28

Last Posted Date: 2025-02-17

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 300

Registration Number: NCT06058299

Locations: 🇵🇭
Care Clinical Trial Group Inc., Dasmariñas, Philippines
🇬🇪
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇵🇭
Tropical Disease Foundation, Makati City, Philippines

and more 19 locations

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

Phase 1

Completed

Conditions: Multi Drug Resistant Tuberculosis
Drug Sensitive Tuberculosis
Pulmonary Disease
Drug-resistant Tuberculosis
Mycobacterium Tuberculosis Infection
Tuberculosis, Pulmonary
Tuberculosis

Interventions: Drug: TBAJ-876
Drug: Midazolam
Drug: Digoxin

First Posted Date: 2022-09-02

Last Posted Date: 2024-10-07

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 28

Registration Number: NCT05526911

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States

Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: TBAJ-587
Drug: Placebo

First Posted Date: 2021-05-18

Last Posted Date: 2023-05-19

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 106

Registration Number: NCT04890535

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Phase 1

Completed

Conditions: Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: TBI-223 Placebo
Drug: TBI-223 1800 mg
Drug: TBI-223 2400mg

First Posted Date: 2021-04-29

Last Posted Date: 2025-06-05

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 28

Registration Number: NCT04865536

Locations: 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

Phase 1

Completed

Conditions: Pulmonary Disease
Drug-resistant Tuberculosis
Tuberculosis, Pulmonary
Tuberculosis
Multi Drug Resistant Tuberculosis
Drug Sensitive Tuberculosis
Mycobacterium Tuberculosis Infection

Interventions: Drug: TBAJ-876 suspension
Drug: Placebo suspension
Drug: TBAJ-876 100 mg tablet
Drug: TBAJ-876 25 mg tablet

First Posted Date: 2020-07-30

Last Posted Date: 2025-06-04

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 137

Registration Number: NCT04493671

Locations: 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

Phase 1

Completed

Conditions: Multi-drug Resistant Tuberculosis

Interventions: Drug: Pretomanid

First Posted Date: 2020-03-16

Last Posted Date: 2024-07-24

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 48

Registration Number: NCT04309656

Locations: 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States

A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary
Tuberculosis, Multidrug-Resistant
Tuberculosis
Tuberculosis, MDR
Drug-Resistant Tuberculosis

Interventions: Drug: Pretomanid
Drug: Bedaquiline
Drug: moxifloxacin
Drug: pyrazinamide

First Posted Date: 2019-11-27

Last Posted Date: 2025-01-17

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 26

Registration Number: NCT04179500

Locations: 🇬🇪
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
🇿🇦
CHRU, Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇿🇦
Isango Lethemba TB Research Unit Empilweni TB Hospital, Port Elizabeth, South Africa

and more 1 locations

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Phase 1

Completed

Conditions: Tuberculosis
Tuberculosis, Pulmonary

Interventions: Drug: TBI-223 oral suspension
Drug: Placebo suspension
Drug: TBI-223 SR Tablet Prototype 1
Drug: TBI-223 SR Tablet Prototype 2
Drug: TBI-223 SR Tablet Prototype 3
Drug: TBI-223 IR Tablet
Drug: TBI-223 enteric capsule

First Posted Date: 2018-11-29

Last Posted Date: 2024-12-09

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 86

Registration Number: NCT03758612

Locations: 🇺🇸
Worldwide Clinical Trials (WCT), San Antonio, Texas, United States

Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Phase 2

Completed

Conditions: Tuberculosis, Pulmonary
Tuberculosis, Multidrug-Resistant
Tuberculosis, MDR
Tuberculosis
Drug-Resistant Tuberculosis

Interventions: Drug: Pretomanid
Drug: HRZE
Drug: Bedaquiline
Drug: HR
Drug: Moxifloxacin
Drug: Pyrazinamide

First Posted Date: 2017-11-09

Last Posted Date: 2024-03-07

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 455

Registration Number: NCT03338621

Locations: 🇧🇷
Evandro Chagas, Rio de Janeiro, Brazil
🇧🇷
FIOCRUZ, Rio de Janeiro, Brazil
🇬🇪
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 23 locations

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: PA-824

First Posted Date: 2017-06-28

Last Posted Date: 2018-08-02

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 6

Registration Number: NCT03202693

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy